Lördag 2 Augusti | 10:02:09 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-30 07:30 Kvartalsrapport 2025-Q3
2025-07-14 - Split QLINEA 1000:1
2025-07-10 - Kvartalsrapport 2025-Q2
2025-06-26 - Årsstämma
2025-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2025-04-14 - Kvartalsrapport 2025-Q1
2025-04-03 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-12 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-03 - Extra Bolagsstämma 2023
2023-06-13 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Q-Linea grundades 2008 och har huvudkontor i Uppsala.
2025-07-29 16:00:00

BLASTID and Q-linea will present groundbreaking results at the #ADLM2025 Conference in Chicago, IL towards ultra-rapid diagnosis of bloodstream infections and sepsis.

Chicago, IL – July 29, 2025 – BLASTID and Q-linea today announce successful proof-of-concept of direct-from-whole-blood ultra-rapid organism isolation, enrichment and phenotypic antibiotic susceptibility testing (AST).

Sepsis and bloodstream infections impact millions of patients globally each year and is one of the deadliest and most expensive conditions treated in hospitals. Rapid sepsis progression means that delay of appropriate treatment significantly increases mortality risk and healthcare costs. BLASTID™ and Q-linea have developed technologies to reduce time to clinically actionable results from days to hours from blood draw, even at ultra-low pathogen concentrations.

Initial work, presented today at the Association for Laboratory Medicine and Diagnostics (ADLM2025) Conference in Chicago, focuses on the clinically-significant ESKAPE bacterial panel. Pathogen isolation and enrichment was achieved using BLASTID’s SPLENDID™ platform with rapid AST performed on Q-linea’s ASTar instrument. Results demonstrate technical feasibility to deliver a full isolation, enrichment, and AST test result with minimum inhibitory concentration (MIC) values in less than 8 hours from patient blood draw.

BLASTID CEO & President, Dr. Paulo Garcia, commented, "It’s all about time & accuracy when it comes to saving lives of sepsis patients. Our active collaboration with Q-linea has demonstrated exciting results in expediting phenotypic testing directly from whole blood. We are eager to provide clinicians with the ability to ‘see the bugs’ and to guide effective and timely patient treatment in as little as 4 hours, compared to 24-48+ hours with today’s available options.”

“These results demonstrate the capability to deliver urgent AST testing on the same shift a sample is taken, with life-saving implications for sepsis patients”, said Q-linea CEO, Stuart Gander. He adds, “The combination of Q-linea’s FDA-cleared rapid AST technology with BLASTID’s sample preparation technology avoids the need for lengthy blood sample culturing, reducing testing time and associated hospital lab costs.”

BLASTID™ & Q-linea Poster A-276 will be presented at ADLM2025 in Chicago on Tuesday, July 29th 2025 at 1:30 PM CST. ePoster is available on the ADLM2025 Mobile App.

This research was, in part, funded by the United States Government, ARPA-H. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the United States Government.

About BLASTID

BLASTID Inc., is a Boston-based Harvard spinout pioneering diagnostic platforms to provide life-saving phenotypic insights to doctors treating patients with bloodstream infections and sepsis. Our ultra-rapid SPLENDID platform is a direct from whole-blood technology that is capable of pathogen isolation and enrichment, single-cell characterization, and antibiotic susceptibility testing (AST). Our work is funded through the ARPA-H DARTS program and integrates advanced microfluidics, novel optics, and predictive AI/ML algorithms for fast Antimicrobial Resistance (AMR) Diagnostics. Ultimately, we will empower doctors with clinically-actionable information to guide effective and timely treatment during the first critical hours of sepsis patient care. For more information, please visit https://www.blastid.life/.

About Q-linea

Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com.